Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 1/2017

01-02-2017

Biochemical investigations in diagnosis and follow up of acromegaly

Authors: Katharina Schilbach, Christian J. Strasburger, Martin Bidlingmaier

Published in: Pituitary | Issue 1/2017

Login to get access

Abstract

Measurements of human growth hormone (GH) and insulin-like growth-factor I (IGF-I) are cornerstones in the diagnosis of acromegaly. Both hormones are also used as biochemical markers in the evaluation of disease activity during treatment. Management of acromegaly is particularly challenging in cases where discordant information is obtained from measurement of GH concentrations following oral glucose load and from measurement of IGF-I. While in some patients biological factors can explain the discrepancy, in many cases issues with the analytical methods seem to be responsible. Assays used by endocrine laboratories to determine concentrations of GH and IGF-I underwent significant changes during the last decades. While generally leading to more sensitive and reproducible methods, these changes also had considerable impact on absolute concentrations measured. This must be reflected by updated decision limits, cut-offs and reference intervals. Since different commercially available assays do not agree very well, method specific interpretation of GH and IGF-I concentrations is required. This complexity in the interpretation of hormone concentrations is not always appropriately reflected in laboratory reports, but also not in clinical guidelines reporting decision limits not related to a specific analytical method. The present review provides an overview about methodological and biological variables affecting the biochemical assessment of acromegaly in diagnosis and follow up.
Literature
1.
Rosario PW (2011) Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary 14(3):217–221PubMedCrossRef
2.
3.
Rajasoorya C et al (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 41(1):95–102CrossRef
4.
Nachtigall L et al (2008) Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 93(6):2035–2041PubMedCrossRef
5.
Reid TJ et al (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol 72(2):203–208CrossRef
6.
Bates AS et al (1993) An audit of outcome of treatment in acromegaly. Q J Med 86(5):293–299PubMed
7.
Swearingen B et al (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83(10):3419–3426PubMed
8.
Colao A et al (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102–152PubMedCrossRef
9.
Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667–674PubMedCrossRef
10.
Szczesniak D, Jawiarczyk-Przybylowska A, Rymaszewska J (2015) The quality of life and psychological, social and cognitive functioning of patients with acromegaly. Adv Clin Exp Med 24(1):167–172PubMedCrossRef
11.
12.
Laws ER Jr., et al (1979) Neurosurgical management of acromegaly. Results in 82 patients treated between 1972 and 1977. J Neurosurg 50(4):454–461PubMedCrossRef
13.
Colao A et al (2006) Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol 65(2):250–256CrossRef
14.
15.
Katznelson L et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951PubMedCrossRef
16.
Giustina A et al (2011) Current management practices for acromegaly: an international survey. Pituitary 14(2):125–133PubMedCrossRef
17.
18.
19.
Salmon WD Jr, Daughaday WH (1957) A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 49(6):825–836PubMed
20.
21.
Ribeiro-Oliveira A Jr, Faje AT, Barkan AL (2011) Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol 164(1):17–22PubMedCrossRef
22.
Freda PU et al (2003) Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 6(4):175–180PubMedCrossRef
23.
Alexopoulou O et al (2008) Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93(4):1324–1330PubMedCrossRef
24.
Elias PC et al (2010) Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Horm Metab Res 42(1):50–55PubMedCrossRef
25.
Sherlock M et al (2009) Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol 71(1):74–81CrossRef
26.
Bianchi A et al (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94(6):2015–2022PubMedCrossRef
27.
Carmichael JD et al (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94(2):523–527PubMedCrossRef
28.
Freda PU et al (2001) Gender and age in the biochemical assessment of cure of acromegaly. Pituitary 4(3):163–171PubMedCrossRef
29.
Dimaraki EV et al (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87(8):3537–3542PubMedCrossRef
30.
Gullu S et al (2004) Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol 150(4):465–471PubMedCrossRef
31.
Donaghy AJ et al (2002) Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol 36(6):751–758PubMedCrossRef
32.
Verrua E et al (2011) GH response to oral glucose tolerance test: a comparison between patients with acromegaly and other pituitary disorders. J Clin Endocrinol Metab 96(1):E83–E88PubMedCrossRef
33.
Manolopoulou J et al (2012) Automated 22-kD growth hormone-specific assay without interference from pegvisomant. Clin Chem 58(10):1446–1456PubMedCrossRef
34.
Minuto FM et al (2012) Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. Pituitary 15(2):215–221PubMedCrossRef
35.
Bancos I et al (2013) Determination of nadir growth hormone concentration cutoff in patients with acromegaly. Endocr Pract 19(6):937–945PubMedCrossRef
36.
Rosario PW, Calsolari MR (2015) Safety and specificity of the growth hormone suppression test in patients with diabetes. Endocr 48(1):329–333CrossRef
37.
Frystyk J, Freda P, Clemmons DR (2010) The current status of IGF-I assays—a 2009 update. Growth Horm IGF Res 20(1):8–18PubMedCrossRef
38.
Bidlingmaier M, Freda PU (2010) Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm IGF Res 20(1):19–25PubMedCrossRef
39.
Ross DA, Wilson CB (1988) Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg 68(6):854–867PubMedCrossRef
40.
Lindholm J et al (1987) Investigation of the criteria for assessing the outcome of treatment in acromegaly. Clin Endocrinol 27(5):553–562CrossRef
41.
Abosch A et al (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83(10):3411–3418PubMedCrossRef
42.
Melmed S et al (1995) Clinical review 75: recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 80(12):3395–3402PubMed
43.
Giustina A et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85(2):526–529PubMed
44.
Giustina A et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148PubMedCrossRef
45.
Endert E et al (2006) Establishment of reference values for endocrine tests–part V: acromegaly. Neth J Med 64(7):230–235PubMed
46.
Freda PU et al (2004) Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 89(2):495–500PubMedCrossRef
47.
Freda PU et al (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 83(11):3808–3816PubMed
48.
Chapman IM et al (1994) Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 78(6):1312–1319PubMed
49.
50.
Wieringa GE, Barth JH, Trainer PJ (2004) Growth hormone assay standardization: a biased view? Clin Endocrinol 60(5):538–539CrossRef
51.
Sheppard MC (2007) Growth hormone assay standardization: an important clinical advance. Clin Endocrinol 66(2):157–161CrossRef
52.
Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57(4):555–559PubMedCrossRef
53.
Markkanen H et al (2006) Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls. Clin Chem 52(3):468–473PubMedCrossRef
54.
Granada ML et al (1990) Assay-dependent results of immunoassayable spontaneous 24-hour growth hormone secretion in short children. Acta Paediatr Scand Suppl 370:63–70 (discussion 71)PubMedCrossRef
55.
Celniker AC et al (1989) Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab 68(2):469–476PubMedCrossRef
56.
Arafat AM et al (2008) Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 93(4):1254–1262PubMedCrossRef
57.
Pokrajac A et al (2007) Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol 67(1):65–70CrossRef
58.
Hattori N et al (1990) Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly. J Clin Endocrinol Metab 70(3):771–776PubMedCrossRef
59.
Costa AC et al (2002) Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 87(7):3142–3147PubMedCrossRef
60.
Grottoli S et al (2003) Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. J Endocrinol Invest 26(2):123–127PubMedCrossRef
61.
Rosario PW, Furtado MS (2008) Growth hormone after oral glucose overload: revision of reference values in normal subjects. Arq Bras Endocrinol Metabol 52(7):1139–1144PubMedCrossRef
62.
Arafat AM et al (2011) Comparison of oral glucose tolerance test (OGTT) 100 g with OGTT 75 g for evaluation of acromegalic patients and the impact of gender on test reproducibility. Clin Endocrinol 75(5):685–691CrossRef
63.
Clemmons DR (2007) IGF-I assays: current assay methodologies and their limitations. Pituitary 10(2):121–128PubMedCrossRef
64.
Quarmby V, Quan C (1999) How much insulin-like growth factor-I (IGF-I) circulates?: impact of standardization on IGF-I assay accuracy. Dev Biol Stand 97:111–118PubMed
65.
Burns C et al (2009) The First International Standard For Insulin-like Growth Factor-1 (IGF-1) for immunoassay: preparation and calibration in an international collaborative study. Growth Horm IGF Res 19(5):457–462PubMedCrossRef
66.
Boero L et al (2012) Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients. Pituitary 15(4):466–471PubMedCrossRef
67.
Bidlingmaier M et al (2014) Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 99(5):1712–1721PubMedCrossRef
68.
69.
Rosario PW (2010) Measurement of basal GH in the diagnosis of acromegaly. Arq Bras Endocrinol Metabol 54(7):668–669PubMedCrossRef
70.
Jenkins D et al (1995) The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol 43(5):517–522CrossRef
71.
72.
Roelfsema F, Veldhuis JD (2016) Growth hormone dynamics in healthy adults are related to age and sex and strongly dependent on body mass index. Neuroendocrinology 103(3–4):335–344PubMed
73.
Peacey SR et al (2001) The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 86(1):259–266PubMedCrossRef
74.
Bates AS et al (1995) Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol 42(4):417–423CrossRef
75.
Dobrashian RD et al (1993) Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly. Clin Endocrinol 38(6):589–593CrossRef
76.
Kaltsas GA et al (2001) Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 86(4):1645–1652PubMedCrossRef
77.
Jorgensen JO et al (1990) Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab 70(6):1616–1623PubMedCrossRef
78.
Laursen T et al (1995) Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. J Clin Endocrinol Metab 80(8):2410–2418PubMed
79.
Johansson JO et al (1996) Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis. Metabolism 45(3):362–369PubMedCrossRef
80.
Feelders RA et al (2005) Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 90(12):6480–6489PubMedCrossRef
81.
Kreutzer J et al (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86(9):4072–4077PubMedCrossRef
82.
Takahashi JA et al (2004) Early postoperative indicators of late outcome in acromegalic patients. Clin Endocrinol 60(3):366–374CrossRef
83.
Espinosa-de-los-Monteros AL et al (2002) Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly. J Neurosurg 97(2):287–292PubMedCrossRef
84.
Hartman ML, Veldhuis JD, Thorner MO (1993) Normal control of growth hormone secretion. Horm Res 40(1–3):37–47PubMedCrossRef
85.
86.
Hoeflich A, Russo VC (2015) Physiology and pathophysiology of IGFBP-1 and IGFBP-2—consensus and dissent on metabolic control and malignant potential. Best Pract Res Clin Endocrinol Metab 29(5):685–700PubMedCrossRef
87.
Clemmons DR (2016) Role of IGF binding proteins in regulating metabolism. Trends Endocrinol Metab 27(6):375–391PubMedCrossRef
88.
Growth Hormone Research S, S Pituitary (2004) Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 89(7):3099–3102CrossRef
89.
Frantz AG, Rabkin MT (1965) Effects of estrogen and sex difference on secretion of human growth hormone. J Clin Endocrinol Metab 25(11):1470–1480PubMedCrossRef
90.
Ho KY et al (1987) Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 64(1):51–58PubMedCrossRef
91.
Faria AC et al (1992) Pulsatile growth hormone release in normal women during the menstrual cycle. Clin Endocrinol 36(6):591–596CrossRef
92.
Ronchi CL et al (2007) Adequacy of current postglucose GH nadir limit (<1 μg/L) to define long-lasting remission of acromegalic disease. Clin Endocrinol 66(4):538–542CrossRef
93.
Dawson-Hughes B et al (1986) Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab 63(2):424–432PubMedCrossRef
94.
Weissberger AJ, Ho KK, Lazarus L (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72(2):374–381PubMedCrossRef
95.
Engstrom BE, Karlsson FA, Wide L (1998) Marked gender differences in ambulatory morning growth hormone values in young adults. Clin Chem 44(6 Pt 1):1289–1295PubMed
96.
Colao A et al (2002) Gender- and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Invest 25(6):532–538PubMedCrossRef
97.
98.
Strasburger CJ et al (2001) Normal values of insulin-like growth factor I and their clinical utility in adults. Horm Res 55(Suppl 2)100–105PubMed
99.
Clemmons DR, JJ Van Wyk (1984) Factors controlling blood concentration of somatomedin C. Clin Endocrinol Metab 13(1):113–143PubMedCrossRef
100.
Parkinson C et al (2002) Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol 57(1):59–64CrossRef
101.
Parkinson C et al (2001) The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86(11):5240–5244PubMedCrossRef
102.
Wiedemann E, Schwartz E (1972) Suppression of growth hormone-dependent human serum sulfation factor by estrogen. J Clin Endocrinol 34:51–58PubMedCrossRef
103.
Clemmons DR et al (1980) Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med 69(4):571–575PubMedCrossRef
104.
Hobbs CJ et al (1993) Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 77(3):776–779PubMed
105.
Ghigo E et al (1996) New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 134(3):352–356PubMedCrossRef
106.
Vierhapper H et al (2003) Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 52(2):181–185PubMedCrossRef
107.
Juul A (2003) Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 13(4):113–170PubMedCrossRef
108.
109.
Galli G et al (2012) Serum insulin-like growth factor-1 concentrations are reduced in severely obese women and raise after weight loss induced by laparoscopic adjustable gastric banding. Obes Surg 22(8):1276–1280PubMedCrossRef
110.
Merimee TJ, Zapf J, Froesch ER (1982) Insulin-like growth factors in the fed and fasted states. J Clin Endocrinol Metab 55(5):999–1002PubMedCrossRef
111.
Smith WJ, Underwood LE, Clemmons DR (1995) Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J Clin Endocrinol Metab 80(2):443–449PubMed
112.
Clemmons DR, Underwood LE (1991) Nutritional regulation of IGF-I and IGF binding proteins. Annu Rev Nutr 11:393–412PubMedCrossRef
113.
Grottoli S et al (2008) Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly. J Endocrinol Invest 31(12):1103–1109PubMedCrossRef
114.
Bartz S et al (2014) Severe acute malnutrition in childhood: hormonal and metabolic status at presentation, response to treatment, and predictors of mortality. J Clin Endocrinol Metab 99(6):2128–2137PubMedPubMedCentralCrossRef
115.
116.
Straus DS, Takemoto CD (1990) Effect of fasting on insulin-like growth factor-I (IGF-I) and growth hormone receptor mRNA levels and IGF-I gene transcription in rat liver. Mol Endocrinol 4(1):91–100PubMedCrossRef
117.
Stoving RK et al (1999) Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J Clin Endocrinol Metab 84(6):2056–2063PubMed
118.
119.
Tonshoff B et al (1995) Deconvolution analysis of spontaneous nocturnal growth hormone secretion in prepubertal children with preterminal chronic renal failure and with end-stage renal disease. Pediatr Res 37(1):86–93PubMedCrossRef
120.
Tonshoff B et al (1997) Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding protein-1 and -2 gene expression in experimental uremia. Endocrinology 138(3):938–946PubMedCrossRef
121.
122.
Hirschberg R, Adler S (1998) Insulin-like growth factor system and the kidney: physiology, pathophysiology, and therapeutic implications. Am J Kidney Dis 31(6):901–919PubMedCrossRef
123.
Powell DR et al (1999) Effects of chronic renal failure and growth hormone on serum levels of insulin-like growth factor-binding protein-4 (IGFBP-4) and IGFBP-5 in children: a report of the Southwest Pediatric Nephrology Study Group. J Clin Endocrinol Metab 84(2):596–601PubMed
124.
Anderwald CH et al (2014) Whole-body insulin sensitivity rather than body-mass-index determines fasting and post-glucose-load growth hormone concentrations. PLoS One 9(12):e115184PubMedPubMedCentralCrossRef
125.
Giustina A et al (1990) Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. J Clin Endocrinol Metab 71(6):1486–1490PubMedCrossRef
126.
Giustina A et al (1991) Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients. Acta Endocrinol 125(5):510–517PubMed
127.
Giustina A et al (1996) Hypothalamic control of growth hormone (GH) secretion in type I diabetic men: effect of the combined administration of GH-releasing hormone and hexarelin, a novel GHRP-6 analog. Endocr Res 22(2):159–174PubMedCrossRef
128.
Giustina A, Wehrenberg WB (1994) Growth Hormone neuroregulation in diabetes mellitus. Trends Endocrinol Metab 5(2):73–78PubMedCrossRef
129.
Giustina A et al (1994) Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II diabetic patients. Metabolism 43(7):893–898PubMedCrossRef
130.
Giustina A et al (1992) Effect of galanin on the growth hormone response to growth hormone-releasing hormone in acromegaly. Metabolism 41(12):1291–1294PubMedCrossRef
131.
Mazziotti G et al (2008) Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: efficacy and safety of the galanin test. Neuroendocrinology 88(4):299–304PubMedCrossRef
132.
Giustina A et al (2015) Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor? Acta Diabetol 52(3):433–443PubMedCrossRef
133.
Rinderknecht E, Humbel RE (1978) The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253(8):2769–2776PubMed
134.
Boni-Schnetzler M et al (1991) Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am J Physiol 260(6 Pt 1):E846–E851PubMed
135.
Janssen JA, Lamberts SW (1999) Is the measurement of free IGF-I more indicative than that of total IGF-I in the evaluation of the biological activity of the GH/IGF-I axis? J Endocrinol Invest 22(4):313–315PubMedCrossRef
136.
Bereket A, Lang CH, Wilson TA (1999) Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 31(2–3):172–181PubMedCrossRef
137.
Van den Berghe GH (1998) Acute and prolonged critical illness are two distinct neuroendocrine paradigms. Verh K Acad Geneeskd Belg 60(6):487–518 (discussion 518–20)PubMed
138.
Voerman HJ et al (1992) Growth hormone: secretion and administration in catabolic adult patients, with emphasis on the critically ill patient. Neth J Med 41(5–6):229–244PubMed
139.
Baxter RC et al (1998) Thirty-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients. Growth Horm IGF Res 8(6):455–463PubMedCrossRef
140.
Ross R et al (1991) Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol 35(1):47–54CrossRef
141.
142.
Van den Berghe G et al (1998) Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 83(2):309–319PubMed
143.
Van den Berghe G et al (1997) The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 82(2):590–599PubMed
144.
145.
Donaghy A et al (1995) Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 21(3):680–688PubMed
146.
Cuneo RC et al (1995) Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. Clin Endocrinol 43(3):265–275CrossRef
Metadata
Title
Biochemical investigations in diagnosis and follow up of acromegaly
Authors
Katharina Schilbach
Christian J. Strasburger
Martin Bidlingmaier
Publication date
01-02-2017
Publisher
Springer US
Published in
Pituitary / Issue 1/2017
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-017-0792-z

Other articles of this Issue 1/2017

Pituitary 1/2017 Go to the issue

ReviewPaper

T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective

ReviewPaper

Update on quality of life in patients with acromegaly

OriginalPaper

Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly

ReviewPaper

Pregnancy and acromegaly

ReviewPaper

Epidemiology of acromegaly: review of population studies

ReviewPaper

Cabergoline in acromegaly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits